Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

0.9976 +0.0225 (+2.31%)
Delayed Quote Updated: 9:38 AM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Telomir Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases
Via ACCESS Newswire
News headline image
Stock Market Today: Nvidia Drags Down Nasdaq Futures—Dollar General, Dell, Best Buy In Focus ↗
U.S. stock futures were swinging on Thursday following Wednesday's advances. Futures of major benchmark indices were largely mixed. 
Via Benzinga
News headline image
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Telomir Pharmaceuticals Stock Ran Up 35% On Wednesday Night ↗
Telomir Pharmaceuticals' shares jumped 35% after promising data showed its lead drug Telomir-1 may offer a safer, dual-action treatment for cancer and aging-related diseases. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Wednesday's after hours session: top gainers and losers ↗
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in
Via ACCESS Newswire
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Most active stocks in Friday's session ↗
Discover the most active stocks in Friday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Falls Over 200 Points; 3M Earnings Top Views ↗
 
Via Benzinga
Topics Stocks
News headline image
On Friday, there are stocks with unusual volume. Let's take a look. ↗
On Friday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
News headline image
Friday's session: top gainers and losers ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Gapping stocks in Friday's session ↗
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
US Stocks Mixed; American Express Posts Upbeat Q2 Results ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin
Via ACCESS Newswire
News headline image
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Higher After Scaling Record Close: American Express, 3M, Charles Schwab Earnings In Focus ↗
U.S. stock futures were positive on Friday after ending higher on Thursday. Futures of major benchmark indices were higher. 
Via Benzinga
News headline image
Telomir Pharma Skyrockets Nearly 139% After-Hours As Cancer Drug Shows Breakthrough Results, Beats Chemo In Human Cell Tests ↗
Following the announcement of promising data regarding Telomir-1, Telomir Pharmaceuticals Inc stock surged 138.84% during after-hours trading on Thursday, 
Via Benzinga
News headline image
Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains ↗
The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Thursday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success for Telomir-1 in Progeria Cell Lines
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.